RetinalGenix signs new laboratory lease with MBC BioLabs

(Image credit: AdobeStock/thodonal)

RetinalGenix has signed a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San Carlos, California. The Retinal Genix plans to use the facility to further the development of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform. The fully equipped laboratory space provides access to world-class scientific equipment and is strategically located close to the Charles River Laboratories vivarium lab facility, providing turnkey solutions for advancing in vivo animal research studies.¹

The lease includes an option for Mission BioCapital, an affiliate of MBC Biolabs, to invest in RetinalGenix

RetinalGenix is engaged in research to repurpose previous commercialized drugs for new indications in dementia, parkinsonism, and macular degeneration. The company holds patents for repurposing various legacy therapeutics that were on the market for over 30 years. These drugs are now being re-evaluated and repurposed through advanced genetic profiling.¹

In the company’s press release¹, Jerry Katzman, MD, Chairman, President, and CEO of RetinalGenix spoke to this milestone, noting the future potential it has. He said, “We are thrilled to join the prestigious cohort of leading-edge bio companies at MBC Biolabs. This opportunity will allow us to accelerate our mission to repurpose FDA-approved therapeutics for new indications, and to explore therapies targeting other ocular and neurodegenerative diseases.”

“RetinalGenix intends to expand Institutional Review Board (IRB) approval of a clinical study to include multiple practices. The facility at MBCBiolab is the perfect laboratory to accelerate the development of our RetinalGenix DNA/GPS platform,” stated Dr Larry Perich, director of the current Florida-based study.¹

Fred Chasalow, PhD, Special Consultant for Therapeutics at RetinalGenix will direct the Company’s MBC Biolabs laboratory activities. Among his many accomplishments, Chasalow is credited with discovering 3 novel steroids. He also serves on the Medical Advisory Board of DNA-GPS, a division of RetinalGenix. Chasalow has a current CDMRP grant to investigate novel neurohormones. CDMRP is a DoD program that funds biomedical research in response to the needs of the public, the military, and the US Congress.¹

Reference:

1. RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs. RetinalGeniX Technologies, Inc. May 5, 2025. Accessed May 5, 2025. https://www.globenewswire.com/news-release/2025/05/05/3073879/0/en/RetinalGenix-Technologies-Inc-Announces-Laboratory-Lease-Agreement-with-Life-Science-Incubator-MBC-BioLabs.html